Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma
Hedwig M. Blommestein(Erasmus University Rotterdam), Sonja Zweegman(Vrije Universiteit Amsterdam)
Cited by 15
Related Papers
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
|Blood Cancer Journal|2021|95
Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010
|Haematologica|2014|57
<sup>18</sup>F-FDG or 3′-Deoxy-3′-<sup>18</sup>F-Fluorothymidine to Detect Transformation of Follicular Lymphoma
|Journal of Nuclear Medicine|2015|33